Philippines Oncology Clinical Trials Market Report 2022 to 2030

Philippines Oncology Clinical Trials Market Analysis

$ 3999

The Philippines oncology clinical trials market is projected to grow from $27.8 Mn in 2022 to $44.4 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022-30. The market will be driven by the growing cancer burden, favorable regulatory environment, and cheaper costs. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Novartis International AG & AstraZeneca plc.

ID: IN10PHCT006 CATEGORY: Clinical Trials GEOGRAPHY: Phillipines AUTHOR: Vidhi Upadhyay

Buy Now

Philippines Oncology Clinical Trials Market Executive Summary

The Philippines oncology clinical trials market is projected to grow from $27.8 Mn in 2022 to $44.4 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022-30. Clinical trials are governed in the Philippines by the Department of Health (DOH) and the Food and Drug Administration (FDA) (FDA). The FDA is a DOH agency in charge of guaranteeing the safety, effectiveness, and quality of food, medicines, cosmetics, and medical devices. According to 2019 projections, the Philippine government supports slightly more than 40% of overall cancer costs, with out-of-pocket payments and private insurance covering the rest (Philippines Statistical Agency, 2020). Cancer is the Philippines' second biggest cause of mortality. Breast, lung, colorectal, liver, and prostate cancers are the most prevalent. Cancer is one of the main causes of mortality in the Philippines, of over 110 Mn people. Cancer was responsible for approximately 150,000 new diagnoses and over 90,000 fatalities in 2020 alone.

Because of its vast population and developing clinical research infrastructure, the Philippines is emerging as a destination for oncology clinical trials. Participation in oncology clinical trials in the nation has increased in recent years, with a focus on diseases such as breast cancer, lung cancer, and leukaemia. There has been a rise in the number of local and foreign pharmaceutical firms and research institutions conducting trials in the country, making it an important site for oncology clinical trials in Southeast Asia. The nation has the potential to become an even more prominent participant in the global cancer research landscape as it continues to invest in clinical research infrastructure and raise public awareness about clinical trials.

philippines oncology clinical trials market analysis

Market Dynamics

Market Growth Drivers

Recognizing the growing cancer burden, the government has recently increased its cancer-fighting efforts, as evidenced by the formation of the National Cancer Control Committee (NCCC), which is comprised of multi-stakeholder representatives from the government, patient organizations, and medical providers. The National Cancer Prevention and Control Action Plan (NCPCAP) 2015-2020 was designed and released by this group. The introduction of the Z-benefit package, as well as the recommendation that the DOH conduct cervical cancer screening and HPV vaccination programs, are key components of the strategy. The proposed National Integrated Cancer Control Strategy Plan for 2021-2030 is now being reviewed in order to properly overcome obstacles in transition and implementation. The growing cancer burden, a huge patient pool, competent healthcare workers, and government support are all key factors for oncology clinical trials in the Philippines. The favorable regulatory environment and cheaper costs also attract multinational corporations. The pandemic's trend toward virtual and decentralized testing might fuel additional expansion.

Market Restraints

In a 2020 WPRO assessment, the Philippines placed last in policy, planning, and care delivery, and ninth out of ten nations in health system governance. There are also several other barriers to the expansion of oncology clinical trials in the Philippines. One of the most significant barriers is the general public's lack of knowledge and comprehension of clinical trials. Many Filipinos are unfamiliar with clinical trials, and there is a need to raise awareness and educate people about the advantages of clinical research. Another barrier is the regulatory framework in the Philippines for clinical studies. Although the government has made steps to shorten the regulatory procedure for clinical trials, acquiring the requisite clearances and licenses for clinical research still involves considerable complexity. This might increase the time and expense of performing clinical studies in the nation.

Competitive Landscape

Key Players

Pfizer Inc.
Novartis International AG
AstraZeneca plc
Merck & Co., Inc.
Roche Holding AG
Eli Lilly and Company
Sanofi S.A.
Bristol Myers Squibb Company
Specialized Therapeutics

Notable Insights

July 2022, Nerlynx (neratinib), an oral medication developed by specialized Therapeutics, has been approved by the Philippines Food and Drug Administration to reduce the risk of recurrence or death in patients with early-stage HER2-positive (HER2+) breast cancer.
In July 2022, The Philippine Food and Drug Administration (FDA) approved alpelisib in combination with fulvestrant for the treatment of postmenopausal women and men with hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-), PIK3CA-mutated, in advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.
In May 2022, Novartis Philippines has launched a PIK3CA Breast Cancer Testing Program.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Philippines Oncology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.